These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35727737)

  • 1. Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children.
    Sun L; Hu J; Liu J; Zhang Q; Wang O; Jiang Y; Xia W; Xing X; Li M
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2571-2579. PubMed ID: 35727737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
    Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
    Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid.
    Xu XJ; Lv F; Liu Y; Wang JY; Ma DD; Asan ; Wang JW; Song LJ; Jiang Y; Wang O; Xia WB; Xing XP; Li M
    J Hum Genet; 2017 Feb; 62(2):205-211. PubMed ID: 27762305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.
    Lin X; Hu J; Zhou B; Wang X; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1873-1882. PubMed ID: 38181430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X.
    Song Y; Zhao D; Xu X; Lv F; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
    Osteoporos Int; 2018 Jun; 29(6):1389-1396. PubMed ID: 29520608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum bone turnover markers and bone mineral density Z-score in children with osteogenesis imperfecta after zoledronic acid treatment.
    Jin J; Yue L; Lu Y; Zhen Z; Wu H; Shan X
    J Investig Med; 2024 Oct; 72(7):715-722. PubMed ID: 38715223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.
    Zhang Y; Hu J; Lin X; Sun L; Yan S; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
    Front Endocrinol (Lausanne); 2022; 13():901925. PubMed ID: 36225201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
    Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in children with osteogenesis imperfecta: a large-sample study.
    Song Y; Zhao D; Li L; Lv F; Wang O; Jiang Y; Xia W; Xing X; Li M
    Osteoporos Int; 2019 Feb; 30(2):461-468. PubMed ID: 30569229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
    Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
    Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
    Liu J; Lin X; Sun L; Zhang Q; Jiang Y; Wang O; Xing X; Xia W; Li M
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1827-1836. PubMed ID: 38198649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing.
    Liu Y; Asan ; Ma D; Lv F; Xu X; Wang J; Xia W; Jiang Y; Wang O; Xing X; Yu W; Wang J; Sun J; Song L; Zhu Y; Yang H; Wang J; Li M
    Osteoporos Int; 2017 Oct; 28(10):2985-2995. PubMed ID: 28725987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
    Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
    Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic variability in patients with osteogenesis imperfecta caused by BMP1 mutations.
    Pollitt RC; Saraff V; Dalton A; Webb EA; Shaw NJ; Sobey GJ; Mughal MZ; Hobson E; Ali F; Bishop NJ; Arundel P; Högler W; Balasubramanian M
    Am J Med Genet A; 2016 Dec; 170(12):3150-3156. PubMed ID: 27576954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
    Kanno J; Saito-Hakoda A; Kure S; Fujiwara I
    J Bone Miner Metab; 2018 May; 36(3):344-351. PubMed ID: 28528406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.